Wikipedia

John D. Hood

John D. Hood is an American medical physiologist and pharmacologist and the founder and chief executive officer of Impact Biomedicines Inc.[1]

John D. Hood
Alma mater
Scientific career
InstitutionsImpact Biomedicines, Inc.

Education and career

edit

Hood received his B.S. in biochemistry and obtained his Ph.D. in medical physiology from Texas A&M University.[2]

Hood started his career as a Director of Research at TargeGen Inc .[3] He was the co-founder and chief scientific officer of Samumed, a private biopharmaceutical company.[4] Now, he is Board Chairman and Co-founder at Endeavor Biomedicines.[5][6][7]

Research

edit

Hood did research on the development of TG101348 for the treatment of JAK2-driven malignancies and found that TG101348 blocked proliferation and colony formation in vitro against cultured and patient-derived cells bearing the JAK2v617F mutations.[8] He also conducted research on tumor regression by targeted gene delivery to the Neovasculature.[9]

Patents

edit

Hood's patents include[10][11] 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof (US9889140B2),[12] Indazole-3-carboxamides and their use as Wnt/beta-catenin signaling pathway inhibitors (US9802916B2),[13] Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof (US9763927B2),[14] β- and γ-diketones and γ-hydroxy ketones as WNT/β-catenin signaling pathway activators (US9884053B2),[15] and 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof (US9855272B2)[16]

Most cited peer-reviewed articles

edit
  • Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nature Reviews Cancer. 2002 Feb;2(2):91-100. According to Google Scholar, this article has been cited 1991 times[17]
  • Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002 Jun 28;296(5577):2404-7.. According to Google Scholar, this article has been cited 1015 times.[17]
  • Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Molecular cell. 1999 Dec 1;4(6):915-24. . According to Google Scholar, this article has been cited 856 times.[17]
  • Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. American Journal of Physiology. Heart and Circulatory Physiology. 1998 Mar 1;274(3):H1054-8. According to Google Scholar, this article has been cited 828 times.[17]

References

edit
  1. ^ "Jobs with Impact Biomedicines". BioSpace. Retrieved 2019-11-08.
  2. ^ "Bloomberg". www.bloomberg.com. Retrieved 2019-11-08.
  3. ^ "Actavalon Announces Appointment of Dr. John Hood to Its Board of Directors – Actavalon". Retrieved 2019-11-08.
  4. ^ Duncan, Amy (March 26, 2019). "How John Hood's Determination to Help Patients Turned $20 million into $7 billion". SDEE. Retrieved 2019-11-08.
  5. ^ Chen, Caroline (2018-01-09). "How biotech CEO John Hood turned failed Sanofi drug into multibillion deal". www.livemint.com. Retrieved 2019-11-08.
  6. ^ "SDEE Presents: Get to Know Your Neighbors With John Hood". Health Device Network. 2019-02-27. Retrieved 2019-11-08.
  7. ^ "Deep Impact: How Passion, Dedication & Good Science Revived a Life-Saving Drug". WuXi XPress: for WuXi news and R&D insights. 2018-03-12. Retrieved 2019-11-08.
  8. ^ Hood, J.; Cao, J.; Chow, C.; Doukas, J.; Hanna, E.; Lohse, D.; Mak, C.; Martin, M.; Stoughton, S.; Tam, B.; Soll, R. (2008-05-20). "Development of TG101348 for the treatment of JAK2-driven malignancies". Journal of Clinical Oncology. 26 (15_suppl): 7083. doi:10.1200/jco.2008.26.15_suppl.7083. ISSN 0732-183X.
  9. ^ Hood, John D.; Bednarski, Mark; Frausto, Ricardo; Guccione, Samira; Reisfeld, Ralph A.; Xiang, Rong; Cheresh, David A. (2002-06-28). "Tumor Regression by Targeted Gene Delivery to the Neovasculature". Science. 296 (5577): 2404–2407. Bibcode:2002Sci...296.2404H. doi:10.1126/science.1070200. ISSN 0036-8075. PMID 12089446. S2CID 3074604.
  10. ^ "John Hood Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 2019-11-08.
  11. ^ Barthel, Wolfgang; Markwardt, Fritz (1975). "Aggregation of blood platelets by adrenaline and its uptake". Biochemical Pharmacology. 24 (20): 1903–1904. doi:10.1016/0006-2952(75)90415-3. PMID 20.
  12. ^ "US9889140B2".
  13. ^ "US9802916B2".
  14. ^ "US9763927B2".
  15. ^ "US9884053B2".
  16. ^ "US9855272B2".
  17. ^ a b c d "Google Scholar author page".
Retrieved from "https://en.wikipedia.org/w/index.php?title=John_D._Hood&oldid=1219317966"